
Cipla's new film reinforces its commitment to reach every patient
HighlightsCipla has launched the second film of its national brand campaign, '1935 Se Desh Ki Sehat Ke Saath,' which commemorates nine decades of promoting access to life-saving treatments and healthcare equity. The latest film, inspired by a real-life incident during devastating landslides in northern India, showcases Cipla's commitment to delivering essential healthcare despite challenging conditions. Filmmaker Shoojit Sircar and Dentsu Creative India collaborated with Cipla to create a narrative that emphasizes the importance of accessible healthcare and the resilience of the human spirit.
Cipla
has unveiled the second film under its
national brand campaign
, '1935 Se Desh Ki Sehat Ke Saath,' celebrating nine decades of championing access to
life-saving treatments
and
healthcare equity
for all.
While the first film paid tribute to the healthcare community and Cipla's enduring role in empowering them, the latest chapter builds on this legacy by bringing to life the company's deep rooted commitment to enabling access across the country.
This film's narrative is inspired by a
real-life story
that unfolded during a natural disaster, capturing Cipla's unwavering resolve to put patients first, no matter the challenge.
At the heart of the film lies a moving incident that occurred during a time of devastating landslides in a remote northern region of India.
Amid harsh conditions and shattered connectivity, Cipla's team braved the odds to swiftly deliver life-saving treatments to those in urgent need. Through this story, the film echoes a powerful message, 'When the mission is the nation, no terrain is too tough.'
To bring this second chapter to life, Cipla collaborated with filmmaker
Shoojit Sircar
and
Dentsu Creative India
.
Achin Gupta, global chief operating officer, Cipla, said, 'It pays tribute to 90 years of people-first healthcare and reaffirms our ongoing commitment to improving lives through science, empathy, and communication.'
Shoojit Sircar, director, said, 'We wanted to show a real moment where care transcends the challenges of a crisis. Stories like these inspire us and highlight the importance of accessible healthcare. At the heart of our storytelling were the human spirit and Cipla's purpose.'
Watch the videos here:
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
28-05-2025
- Business Standard
These 5 pharma stocks can fall up to 12% as technical charts flag caution
Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for. Premium Rex Cano Mumbai Listen to This Article Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma are the 5 pharma stocks that have flagged a caution signal on the technical charts. Technically, these 5 stocks have seen a negative crossover of the key momentum oscillators like - the Relative Strength Index (RSI), Stochastic Slow or the Moving Average Convergence-Divergence (MACD) on the daily scale. Negative crossover of key momentum oscillators, coupled with violation of key support levels tends to weigh on the stock sentiment. Here's a detailed technical analysis of each of these 5 stocks - Abbott India, Aurobindo Pharma, Cipla, Dr Lal


Time of India
26-05-2025
- Time of India
Cipla's new film reinforces its commitment to reach every patient
HighlightsCipla has launched the second film of its national brand campaign, '1935 Se Desh Ki Sehat Ke Saath,' which commemorates nine decades of promoting access to life-saving treatments and healthcare equity. The latest film, inspired by a real-life incident during devastating landslides in northern India, showcases Cipla's commitment to delivering essential healthcare despite challenging conditions. Filmmaker Shoojit Sircar and Dentsu Creative India collaborated with Cipla to create a narrative that emphasizes the importance of accessible healthcare and the resilience of the human spirit. Cipla has unveiled the second film under its national brand campaign , '1935 Se Desh Ki Sehat Ke Saath,' celebrating nine decades of championing access to life-saving treatments and healthcare equity for all. While the first film paid tribute to the healthcare community and Cipla's enduring role in empowering them, the latest chapter builds on this legacy by bringing to life the company's deep rooted commitment to enabling access across the country. This film's narrative is inspired by a real-life story that unfolded during a natural disaster, capturing Cipla's unwavering resolve to put patients first, no matter the challenge. At the heart of the film lies a moving incident that occurred during a time of devastating landslides in a remote northern region of India. Amid harsh conditions and shattered connectivity, Cipla's team braved the odds to swiftly deliver life-saving treatments to those in urgent need. Through this story, the film echoes a powerful message, 'When the mission is the nation, no terrain is too tough.' To bring this second chapter to life, Cipla collaborated with filmmaker Shoojit Sircar and Dentsu Creative India . Achin Gupta, global chief operating officer, Cipla, said, 'It pays tribute to 90 years of people-first healthcare and reaffirms our ongoing commitment to improving lives through science, empathy, and communication.' Shoojit Sircar, director, said, 'We wanted to show a real moment where care transcends the challenges of a crisis. Stories like these inspire us and highlight the importance of accessible healthcare. At the heart of our storytelling were the human spirit and Cipla's purpose.' Watch the videos here:


News18
21-05-2025
- News18
Natco Pharma, Cipla, Other Pharma Stocks Surge Up To 4% As US Authorities Aim To Cut Drug Prices
Reported By : Last Updated: May 21, 2025, 12:32 IST Pharma stocks in India rallied on May 21 Pharma Stocks Rise: Pharma stocks in India rallied on May 21 after the US Department of Health and Human Services (HHS) announced efforts to implement an executive order aimed at reducing healthcare costs. The HHS is urging drugmakers to align US prices for brand-name drugs—specifically those without generic or biosimilar competition—with the lowest prices offered in comparable OECD countries. This development came as a relief for Indian generic and biosimilar manufacturers, as the proposed pricing reforms target only branded drugs, leaving generics unaffected. According to two analysts quoted by Reuters, the clarity around exclusions for generics helped lift market sentiment. As a result, the Nifty Pharma index rose 1.7%, recovering from a 1.3% decline in the previous session, with 18 of its 20 constituents closing in the green. Gland Pharma led the gains, trading 3.5% higher at Rs 1,551.40. Shares of Natco Pharma and Cipla were up 2.39% and 2.32% at Rs 890 and Rs 1,491, respectively. Biocon and Granules India each rose over 2%, while Sun Pharma gained 2% ahead of its Q4 results, trading at Rs 1,742. The HHS policy proposes that US prices for select brand-name drugs be benchmarked against prices in countries with a GDP per capita of at least 60% that of the US. While the initiative has roots in former President Donald Trump's push to lower drug prices by 59% to 90%, experts believe the plan could face legal challenges and be difficult to implement. Swipe Left For Next Video View all Nonetheless, the news triggered a broad-based rally in Indian pharma stocks on expectations that generic and biosimilar manufacturers will remain insulated from pricing pressure in the US. Disclaimer: Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. Stay updated with all the latest news on the Stock Market, including market trends, Sensex and Nifty updates, top gainers and losers, and expert analysis. Get real-time insights, financial reports, and investment strategies—only on News18. News business » markets Natco Pharma, Cipla, Other Pharma Stocks Surge Up To 4% As US Authorities Aim To Cut Drug Prices